- About us
- Clinical trials
- News & Publications
Nanrilkefusp alfa (formerly SOT101) is a subcutaneously-administered IL-15 superagonist, that is fused to the sushi+ domain of the IL-15 receptor α.
Nanrilkefusp alfa is designed to selectively bind only to cytotoxic T and NK cells, while avoiding other cell types that are associated with adverse events, and its optimized half-life may improve efficacy by limiting T cell exhaustion.
SOTIO is exploring the use of nanrilkefusp alfa in combination with cell therapies, and also in conjunction with partners who are developing treatment modalities with a synergistic mode of action.